Skip to main content
Equibles
CTNM logo

CTNM · Contineum Therapeutics, Inc.

Track CTNM — free

Use CTNM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CTNM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.65 -0.07 (-0.55%) At close · Oct 6
Russell 2000 member Rebalance outlook locked
Market Cap
$494.34M
Shares
37.62M
Volume · Oct 6 761.92K Avg daily vol (3M) 501.02K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$12.65 Open$12.88 Day$12.17–12.88 52W close$9.17–17.57 Avg vol 30d609K Short int2.4M · 6.5% float · 6.9d Short vol72% Last earningsOct 30, 2025 DataApr 2024–Oct 2026 Filing10-Q · Jul 30

Up next

Latest filing: 10-Q
filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$57.56M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-10.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$236.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+44.7%
Year over year · more shares
Price change (1Y)
+12.1%
Trailing year
Short interest
6.5%
Latest settlement · 6.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.57
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg −15%
below
RSI (14) 41
neutral
MACD trend Positive
52-week position 41%
mid-range
Momentum
relative strength
Weak
1-month return −21%
trailing
6-month return −5%
trailing
YTD return +11%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $15 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.50% of float · ▲ +4.4% MoM · 6.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
102 holders — near 2-yr high, broad support
Squeeze score 54
elevated · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth +0%
Y/Y
Free cash flow $-55.5M
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −35%
past year
ATR 8.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
41 Neutral
MACD trend
Positive Bullish
52-week position
41% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $15 › 200d $14 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.50% of float · ▲ +4.4% MoM · 6.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
102 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $9 Now $13 · 41% Range high $18
vs 200-day avg -8% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CTNM
Contineum Therapeutics, Inc.
this stock
$494.34M +10.7% -100.0% — 6.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +10.8% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.3% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +535.7% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
102
% held
81.2%
Net QoQ
-6.6K sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
105
View
Short & Settlement
Short Interest Rising
Shares short
2.4M
Days to cover
6.9d
Change
+102.8K sh
View
Short Volume
Short vol %
72%
As of
Oct 6, 2026
Short Total
View
Fails to Deliver
FTD shares
40
Value
$703
As of
Sep 4, 2026
View
Off-Exchange
Off-exchange %
43.2%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-60.0M
EPS diluted
$-2.17
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 14, 2026
This year
13
View
Proposed Sales
Value
$56.0K
Shares
4.2K
Filed
Oct 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Jun 9, 2026
View
Investor Relations
Latest news
Contineum Therapeutics Reports Ph…
Published
Sep 14, 2026
View

Performance

5D 20D 120D MTD YTD
CTNM +10.0% -20.6% -4.5% -5.7% +10.7%
SPY +2.0% +1.7% +11.3% +2.2% +14.3%
vs SPY +8.1% -22.4% -15.8% -7.9% -3.6%
Key facts CIK 1855175 CUSIP 21217B100 13F (30d) 1 filings 1 filers Visit website Investor relations